| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
|
Sadiq, Muhammad W.
|
|
2016
|
44 |
2 |
p. 69-79
|
article
|
| 2 |
Editorial to the themed issue on focus on infectious disease
|
Bonate, Peter
|
|
2017
|
44 |
2 |
p. 67-68
|
article
|
| 3 |
Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole$$^{1}$$1
|
Bayard, David S.
|
|
2016
|
44 |
2 |
p. 95-111
|
article
|
| 4 |
Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule
|
Bergman, Kimberly L.
|
|
2017
|
44 |
2 |
p. 153-160
|
article
|
| 5 |
Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule
|
Bergman, Kimberly L.
|
|
|
44 |
2 |
p. 153-160
|
article
|
| 6 |
PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside
|
Bulik, Catharine C.
|
|
2017
|
44 |
2 |
p. 161-177
|
article
|
| 7 |
Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis
|
Kovanda, Laura L.
|
|
2017
|
44 |
2 |
p. 143-151
|
article
|
| 8 |
Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza
|
Smith, Amber M.
|
|
2016
|
44 |
2 |
p. 81-93
|
article
|
| 9 |
The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model
|
Chen, Chunli
|
|
2017
|
44 |
2 |
p. 133-141
|
article
|
| 10 |
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles
|
Bush, Karen
|
|
2017
|
44 |
2 |
p. 113-132
|
article
|
Journal description